Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.14
OCR's Cash to Debt is ranked higher than
62% of the 245 Companies
in the Global Medical Care industry.

( Industry Median: 0.24 vs. OCR: 0.14 )
OCR' s 10-Year Cash to Debt Range
Min: 0.05   Max: 67.66
Current: 0.14

0.05
67.66
Equity to Asset 0.40
OCR's Equity to Asset is ranked higher than
67% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. OCR: 0.40 )
OCR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.88
Current: 0.4

0.31
0.88
F-Score: 4
Z-Score: 2.51
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.95
OCR's Operating margin (%) is ranked higher than
64% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 9.14 vs. OCR: 4.95 )
OCR' s 10-Year Operating margin (%) Range
Min: 1.33   Max: 12.02
Current: 4.95

1.33
12.02
Net-margin (%) -0.72
OCR's Net-margin (%) is ranked higher than
60% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. OCR: -0.72 )
OCR' s 10-Year Net-margin (%) Range
Min: -1.73   Max: 8.11
Current: -0.72

-1.73
8.11
ROE (%) -1.58
OCR's ROE (%) is ranked higher than
59% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. OCR: -1.58 )
OCR' s 10-Year ROE (%) Range
Min: -2.78   Max: 12.25
Current: -1.58

-2.78
12.25
ROA (%) -0.65
OCR's ROA (%) is ranked higher than
59% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 3.59 vs. OCR: -0.65 )
OCR' s 10-Year ROA (%) Range
Min: -1.44   Max: 6.87
Current: -0.65

-1.44
6.87
ROC (Joel Greenblatt) (%) 21.92
OCR's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 15.98 vs. OCR: 21.92 )
OCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.17   Max: 43.64
Current: 21.92

5.17
43.64
Revenue Growth (%) 1.50
OCR's Revenue Growth (%) is ranked higher than
63% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. OCR: 1.50 )
OCR' s 10-Year Revenue Growth (%) Range
Min: -0.4   Max: 42.3
Current: 1.5

-0.4
42.3
EBITDA Growth (%) 29.10
OCR's EBITDA Growth (%) is ranked higher than
95% of the 172 Companies
in the Global Medical Care industry.

( Industry Median: 6.70 vs. OCR: 29.10 )
OCR' s 10-Year EBITDA Growth (%) Range
Min: -21.8   Max: 37.6
Current: 29.1

-21.8
37.6
EPS Growth (%) 86.60
OCR's EPS Growth (%) is ranked higher than
96% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 11.70 vs. OCR: 86.60 )
OCR' s 10-Year EPS Growth (%) Range
Min: -49.6   Max: 86.6
Current: 86.6

-49.6
86.6
» OCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OCR Guru Trades in Q3 2013

Joel Greenblatt 87,071 sh (New)
Steven Cohen 5,429 sh (New)
James Barrow 4,450,969 sh (+7.22%)
Chuck Royce 66,899 sh (unchged)
Jean-Marie Eveillard 851,300 sh (-55.65%)
Jim Simons 90,200 sh (-78.38%)
First Pacific Advisors 836,500 sh (-82.29%)
Steven Romick 714,900 sh (-83.28%)
Wallace Weitz 113,700 sh (-84.78%)
» More
Q4 2013

OCR Guru Trades in Q4 2013

Pioneer Investments 315,295 sh (New)
Jim Simons 248,000 sh (+174.94%)
Steven Cohen 8,361 sh (+54.01%)
James Barrow 4,506,812 sh (+1.25%)
Chuck Royce 67,299 sh (+0.6%)
Jean-Marie Eveillard 851,300 sh (unchged)
Steven Romick Sold Out
Wallace Weitz Sold Out
Joel Greenblatt 11,932 sh (-86.3%)
First Pacific Advisors 1,100 sh (-99.87%)
» More
Q1 2014

OCR Guru Trades in Q1 2014

Paul Tudor Jones 232,334 sh (New)
Steven Cohen 34,457 sh (+312.12%)
Jim Simons 482,300 sh (+94.48%)
Pioneer Investments 515,458 sh (+63.48%)
James Barrow 4,800,283 sh (+6.51%)
First Pacific Advisors Sold Out
Jean-Marie Eveillard 846,300 sh (-0.59%)
Chuck Royce 59,999 sh (-10.85%)
Joel Greenblatt 3,386 sh (-71.62%)
» More
Q2 2014

OCR Guru Trades in Q2 2014

Joel Greenblatt 48,646 sh (+1336.68%)
Pioneer Investments 689,748 sh (+33.81%)
James Barrow 4,996,755 sh (+4.09%)
Jean-Marie Eveillard 844,500 sh (-0.21%)
Chuck Royce 56,599 sh (-5.67%)
Jim Simons 454,900 sh (-5.68%)
Paul Tudor Jones 100,564 sh (-56.72%)
» More
» Details

Insider Trades

Latest Guru Trades with OCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 1336.68%0.04%$57.54 - $66.51 $ 64.073%48646
Joel Greenblatt 2014-03-31 Reduce -71.62%0.01%$56.55 - $64.54 $ 64.076%3386
Wallace Weitz 2013-12-31 Sold Out 0.24%$53.81 - $60.39 $ 64.0712%0
Joel Greenblatt 2013-12-31 Reduce -86.3%0.14%$53.81 - $60.39 $ 64.0712%11932
Wallace Weitz 2013-09-30 Reduce -84.78%1.19%$47.68 - $56.28 $ 64.0720%113700
Joel Greenblatt 2013-09-30 New Buy0.16%$47.68 - $56.28 $ 64.0720%87071
Jean-Marie Eveillard 2013-09-30 Reduce -55.65%0.16%$47.68 - $56.28 $ 64.0720%851300
Wallace Weitz 2013-06-30 Reduce -52.62%1.37%$40.82 - $47.97 $ 64.0743%746920
Joel Greenblatt 2013-06-30 Sold Out 0.25%$40.82 - $47.97 $ 64.0743%0
Joel Greenblatt 2013-03-31 New Buy0.25%$36.1 - $40.72 $ 64.0766%122850
Joel Greenblatt 2012-12-31 Sold Out 0.02%$32.98 - $36.59 $ 64.0784%0
Joel Greenblatt 2012-09-30 Reduce -80.66%0.1%$30.68 - $35.53 $ 64.0798%10660
Joel Greenblatt 2012-06-30 New Buy0.13%$29.5 - $36.01 $ 64.0793%55131
Ray Dalio 2012-06-30 Sold Out 0.06%$29.5 - $36.01 $ 64.0793%0
Joel Greenblatt 2012-03-31 Sold Out 0.2%$32.51 - $35.56 $ 64.07101%0
Ray Dalio 2012-03-31 Add 1622.17%0.05%$32.51 - $35.56 $ 64.07101%101281
David Dreman 2011-12-31 Sold Out 0.06%$21.62 - $35.05 $ 64.07114%0
Joel Greenblatt 2011-12-31 Reduce -20.99%0.05%$21.62 - $35.05 $ 64.07114%47467
Ray Dalio 2011-12-31 New Buy$21.62 - $35.05 $ 64.07114%5881
Joel Greenblatt 2011-09-30 Add 239.78%0.18%$25.21 - $32.98 $ 64.07120%60077
Wallace Weitz 2011-06-30 Reduce -49.78%2.77%$30.42 - $32.86 $ 64.07104%2038540
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Omnicare Inc

Steven Romick Comments on Omnicare - Jul 29, 2013

Ultimately, we pay more attention to the underlying financial performance of the companies in our investment portfolio than we do their stock charts and in one instance, Omnicare (OCR), the largest supplier of pharmaceuticals to patients in nursing homes, delivered in spades. New management came in several years ago and began executing on a business plan that revolved around basic blocking and tackling to improve performance. While the engineer of the turnaround, John Figueroa, has handed off the plan to his successor, the momentum remained intact under the present CEO, John Workman. The company has lowered costs, reduced customer churn, won new accounts and essentially built the best mousetrap in the institutional pharmacy space. The net result is that all of the aforementioned improvements in aggregate have manifested themselves in the form of higher and more consistent earnings. Those achievements and the belief that the company's future continues to look bright are reflected in a stock price that has more than doubled from our original cost.

From Steven Romick's FPA Crescent Fund second quarter commentary.
Check out Steven Romick latest stock trades

Top Ranked Articles about Omnicare Inc

Steven Romick’s Third Quarter Sells at FPA Crescent Fund
The third quarter portfolio update of the FPA Crescent Fund, led by Guru Steven Romick of First Pacific Advisors, lists 53 stocks. The fund’s total value is $6.9 billion, with a quarter-over-quarter turnover of 4%. The portfolio is currently weighted with top three sectors: financial services at 19.6%, consumer defensive at 17% and healthcare at 16%. Steven Romick has averaged a return of 16.52% over 12 months; First Pacific Advisors is averaging 18.84%. Read more...
Waiting for Gold Rain, Wally Weitz Does "Unnaturally Well"
“Investing is a marathon,” Guru Wallace Weitz told the Weitz Fund shareholders in his second quarter letter, adding: “We face an ongoing series of decisions as to which companies to own, what price to pay, and when to be disciplined about holding out for the right opportunity. The fact that several of our stocks have performed unnaturally well this year gives us a measure of “cover” for our defensive positioning. We feel very confident that our patient, conservative approach will continue to serve us well. Believe me, when stocks become truly cheap again, we will follow Warren Buffett’s advice: Read more...

Ratios

vs
industry
vs
history
P/B 2.30
OCR's P/B is ranked higher than
70% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 2.96 vs. OCR: 2.30 )
OCR' s 10-Year P/B Range
Min: 0.6   Max: 2.97
Current: 2.3

0.6
2.97
P/S 1.12
OCR's P/S is ranked higher than
72% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. OCR: 1.12 )
OCR' s 10-Year P/S Range
Min: 0.33   Max: 1.43
Current: 1.12

0.33
1.43
PFCF 13.00
OCR's PFCF is ranked higher than
86% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 34.00 vs. OCR: 13.00 )
OCR' s 10-Year PFCF Range
Min: 4.79   Max: 71.06
Current: 13

4.79
71.06
EV-to-EBIT 24.67
OCR's EV-to-EBIT is ranked higher than
75% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 26.73 vs. OCR: 24.67 )
OCR' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 69.6
Current: 24.67

8.9
69.6
Shiller P/E 82.80
OCR's Shiller P/E is ranked higher than
71% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. OCR: 82.80 )
OCR' s 10-Year Shiller P/E Range
Min: 9.31   Max: 89.47
Current: 82.8

9.31
89.47
Current Ratio 1.70
OCR's Current Ratio is ranked higher than
79% of the 170 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. OCR: 1.70 )
OCR' s 10-Year Current Ratio Range
Min: 0.9   Max: 9.8
Current: 1.7

0.9
9.8
Quick Ratio 1.32
OCR's Quick Ratio is ranked higher than
74% of the 170 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. OCR: 1.32 )
OCR' s 10-Year Quick Ratio Range
Min: 0.73   Max: 9.04
Current: 1.32

0.73
9.04

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.15
OCR's Dividend Yield is ranked lower than
65% of the 146 Companies
in the Global Medical Care industry.

( Industry Median: 1.51 vs. OCR: 1.15 )
OCR' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.31
Current: 1.15

0.15
1.31
Dividend Payout 0.70
OCR's Dividend Payout is ranked higher than
75% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. OCR: 0.70 )
OCR' s 10-Year Dividend Payout Range
Min: 0.03   Max: 0.95
Current: 0.7

0.03
0.95
Dividend growth (3y) 78.00
OCR's Dividend growth (3y) is ranked higher than
98% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 4.00 vs. OCR: 78.00 )
OCR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 78
Current: 78

0
78
Yield on cost (5-Year) 16.16
OCR's Yield on cost (5-Year) is ranked higher than
97% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 1.91 vs. OCR: 16.16 )
OCR' s 10-Year Yield on cost (5-Year) Range
Min: 2.02   Max: 17.64
Current: 16.16

2.02
17.64
Share Buyback Rate 2.20
OCR's Share Buyback Rate is ranked higher than
93% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. OCR: 2.20 )
OCR' s 10-Year Share Buyback Rate Range
Min: 2.2   Max: -11
Current: 2.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
OCR's Price/DCF (Projected) is ranked higher than
90% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 53.00 vs. OCR: 1.10 )
OCR' s 10-Year Price/DCF (Projected) Range
Min: 0.39   Max: 7
Current: 1.1

0.39
7
Price/Median PS Value 1.70
OCR's Price/Median PS Value is ranked lower than
52% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 1.20 vs. OCR: 1.70 )
OCR' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 6.84
Current: 1.7

0.53
6.84
Earnings Yield (Greenblatt) 4.10
OCR's Earnings Yield (Greenblatt) is ranked higher than
59% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 5.20 vs. OCR: 4.10 )
OCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 11.3
Current: 4.1

1.4
11.3
Forward Rate of Return (Yacktman) 10.30
OCR's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 11.21 vs. OCR: 10.30 )
OCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.3   Max: 23.1
Current: 10.3

-5.3
23.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:OMN.Germany
Omnicare Inc was formed in 1981. It is a healthcare services company that provides complex pharmaceutical care. It operates in two primary businesses, Long-Term Care Group and Specialty Care Group. Through LTC, Omnicare is the provider of pharmaceuticals and related pharmacy and ancillary services to long-term care facilities as well as chronic care facilities and other settings. SCG provides commercialization services for the biopharmaceutical industry in addition to end-of-life pharmaceutical care management for hospice care agencies. With respect to its clinical services, the Company provides pharmacy consulting, including monthly patient drug therapy evaluations, assist in compliance with state and federal regulations and provide proprietary clinical and health management programs. LTC also provides a suite of technology solutions based largely on its Omniview web-based platform that is intended to improve the efficiency of its customers' operations through such tools as the electronic ordering of prescription refills, proof-of-delivery tracking, and real-time validation of Medicare Part D coverage, among others. LTC also provides a number of other products and services, including intravenous medications and nutrition products (infusion therapy products and services), respiratory therapy services, medical supplies and equipment (including billing the Medicare Part B program for eligible patients) and clinical care planning. The Company also provides pharmaceutical case management services for retirees, employees and dependents who have drug benefits under corporate-sponsored healthcare programs. SCG touches a broad spectrum of the healthcare continuum, serving the needs of biopharmaceutical manufacturers, physicians, nurses, caregivers and patients. Its services are largely centered on the specialty pharmaceutical market. These services are based on five platforms: brand support services, third party logistics, patient assistance programs, specialty pharmacy and disease management for end-of-life care. Its brand support services, third party logistics and patient assistance programs are integrated, fee-for-service platforms which focus on helping the drug manufacturer to market, to distribute and obtain reimbursement for their products. In its specialty pharmacy platform, the Commpany provides dispensing of specialized pharmaceuticals that are high cost, have complex reimbursement and supply chain challenges, have limited patient populations and are not available through normal retail channels. These specialized drugs deal primarily with specific categories of drugs and disease states, such as rheumatoid arthritis, multiple sclerosis, oncology and growth hormones. LTC's customers consist of skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other healthcare service providers. The Company's largest competitor nationally is PharMerica Corporation. It a
» More Articles for OCR

Headlines

Articles On GuruFocus.com
It's Time to Follow Chris Davis and Buy Laboratory Corp Jan 15 2014 
Steven Romick’s Third Quarter Sells at FPA Crescent Fund Oct 17 2013 
Waiting for Gold Rain, Wally Weitz Does "Unnaturally Well" Sep 23 2013 
First Pacific Advisors’ Major Selling and Reductions in Second Quarter Aug 15 2013 
Steven Romick Comments on Omnicare Jul 29 2013 
Steven Romick on WealthTrack Oct 20 2012 
Weekly CEO Buys Highlight: SYMC, TDY, PNK, FNFG, OCR Aug 04 2012 
Weitz Partners Value Fund Commentary: CVS, TGT, BRK.A, BRK.B Nov 11 2011 
Daily Dividend Report: HNZ, OCR, SEIC, FPTB, EDE, FISI May 26 2011 
Wallace Weitz Finds Value in These Stocks: LINTA, OCR, RWT, BRK.B, LBTYK, MSFT Dec 14 2010 

More From Other Websites
Charles River Laboratories (CRL) Jumps: Stock Moves 5% Higher Aug 08 2014
Wall Street Transcript Interview with Christopher J. Reading, the President and CEO of U.S. Physical... Aug 04 2014
OMNICARE INC Financials Jul 29 2014
Omnicare Q2 Earnings Beat, Revs up on Strong Segment Sales Jul 24 2014
Omnicare Reports Second-Quarter 2014 Financial Results Jul 23 2014
OMNICARE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 23 2014
Omnicare Reports Second-Quarter 2014 Financial Results Jul 23 2014
Q2 2014 Omnicare, Inc. Earnings Release - Before Market Open Jul 23 2014
Omnicare Reports Second-Quarter 2014 Financial Results Jul 23 2014
Politics fade as earnings take over Jul 18 2014
Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest Jul 07 2014
Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest Jul 07 2014
OMNICARE INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2014
Omnicare to Report Second-Quarter 2014 Financial Results and Hold Conference Call on Wednesday, July... Jul 01 2014
Omnicare to Report Second-Quarter 2014 Financial Results and Hold Conference Call on Wednesday, July... Jul 01 2014
Omnicare agrees to $124M deal for alleged kickback Jun 25 2014
Omnicare agrees to $124M deal for alleged kickback Jun 25 2014
[$$] Omnicare Paying $124 Million to Settle Claims Jun 25 2014
Omnicare in $124 mln settlement over alleged kickbacks Jun 25 2014
Omnicare to pay $124M to settle false billings allegations Jun 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide